Response Genetics, Inc. Achieves Milestone Payments Totaling $1,000,000 for Services Provided to GlaxoSmithKline (GSK) in the Development of BRAF-Inhibitor Tafinlar® (dabrafenib)
6/4/2013 9:36:40 AM
More...
|
Response Genetics, Inc. Announces Presentations at the American Society of Clinical Oncology 2013 Annual Meeting
5/20/2013 9:48:35 AM
More...
|
Response Genetics, Inc. Announces Contract With Blue Shield of California
5/16/2013 9:26:26 AM
More...
|
Response Genetics, Inc. Announces First Quarter 2013 Financial Results
5/14/2013 9:14:42 AM
More...
|
Response Genetics, Inc. to Present at the 2013 UBS Global Healthcare Conference
5/8/2013 9:34:48 AM
More...
|
Response Genetics, Inc. to Release First Quarter 2013 Financial Results and Host Conference Call on May 14, 2013
5/6/2013 9:24:21 AM
More...
|
Response Genetics, Inc. to Present at the 25th Annual ROTH Conference
3/12/2013 12:54:23 PM
More...
|
Response Genetics, Inc. to Release Fourth Quarter and Year-End 2012 Financial Results and Host Conference Call on March 21, 2013
3/7/2013 11:43:52 AM
More...
|
Response Genetics, Inc. to Present at the Canaccord Genuity Medical Technology and Diagnostics Forum
11/30/2012 9:29:25 AM
More...
|
Response Genetics, Inc. Announces Third Quarter Financial Results
11/13/2012 10:03:25 AM
More...
|
|